FDA Grants Neladalkib Accelerated Approval

FDA granted accelerated approval to oral ALK inhibitor neladalkib for specified previously treated ALK-positive advanced NSCLC. In ALKOVE-1, confirmed response was 49% among 67 post-alectinib patients and 32% among 155 patients previously exposed to…




